Loading…
Loading…
FRX.TO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for FRX.TO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FRX.TO and 80,000+ other tickers.
See exactly how FRX.TO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FRX.TO and 80,000+ other tickers.
Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.
- Administration of PEDMARK Approximately Six Hours After Cisplatin was Shown to Be Safe and Easily Integrated into Care for Adults with Head and Neck Cancers (HNC) - - Early Signals of Hearing Preservation Highlight the Potential of PEDMARK to Address Cisplatin-Induced Hearing Loss, a Critical Survivorship Gap, Without Compromising Cisplatin's Established Antitumor Activity - - Majority of High-Risk Patients Receiving PEDMARK Demonstrated No Measurable Hearing Loss During or After Treatment Despite Prevalence of Baseline Hearing Impairment - RESEARCH TRIANGLE PARK, N.
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –
RESEARCH TRIANGLE PARK, N. C. , Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC) (TSX: FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec's outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company's previously announced underwritten public offering in the United States and concurrent private placement in Canada, closed on November 17 and 18, 2025, respectively.